Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Geri Gentry on Sep 12th, 2026

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $40.6250.

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group lifted their price objective on Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen upped their target price on Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Guggenheim boosted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday.

Get Our Latest Stock Report on Roivant Sciences

Roivant Sciences Price Performance

NASDAQ ROIV opened at $40.82 on Friday. The stock has a market capitalization of $29.49 billion, a PE ratio of -77.02 and a beta of 1.12. Roivant Sciences has a 1 year low of $13.81 and a 1 year high of $42.50. The business’s 50-day moving average is $35.79 and its 200 day moving average is $31.62.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities research analysts anticipate that Roivant Sciences will post -2 earnings per share for the current year.

Insider Activity at Roivant Sciences

In other news, Director Daniel Gold sold 12,380 shares of Roivant Sciences stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total transaction of $436,766.40. Following the sale, the director owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mayukh Sukhatme sold 144,756 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the transaction, the insider owned 18,630,739 shares in the company, valued at $679,649,358.72. This represents a 0.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055,913 shares of company stock worth $107,261,258. 8.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Roivant Sciences in the fourth quarter worth $47,000. Parallel Advisors LLC lifted its position in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the period. CIBC Private Wealth Group LLC lifted its position in Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the period. Finally, Clearstead Advisors LLC boosted its holdings in shares of Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after buying an additional 1,704 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.